荃銀高科(300087.SZ):與先正達在科研資源、MAP業務等方面協同力度不斷加強
格隆匯4月2日丨荃銀高科(300087.SZ)在投資者互動平臺表示,公司與先正達在科研資源、MAP業務、種肥藥的銷售等方面協同力度不斷加強,公司作爲先正達種業板塊的重要成員,積極與其開展生物育種技術方面研發與合作,進一步做大做強。公司充分發揮上市公司資本運作優勢,圍繞種業積極進行兼併重組,促進企業做大做強,通過“內生”和 “外延”雙輪驅動,助力公司實現長期發展目標。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.